Altimmune ALT EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Altimmune’s reported figures.
Based on trailing twelve months.
The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Altimmune's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Altimmune's EBITDA margin?
- Altimmune (ALT) reported EBITDA margin of -230,187.8% in Q4 2025.
- How has Altimmune's EBITDA margin changed year-over-year?
- Altimmune's EBITDA margin increased by 55.3% year-over-year, from -514,670% to -230,187.8%.
- What is the long-term trend for Altimmune's EBITDA margin?
- Over 5 years (2020 to 2025), Altimmune's EBITDA margin has grown at a 222.1% compound annual growth rate (CAGR), from -664.3% to -230,187.8%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.